Drug intelligence / Profile preview

4'-hydroxy-3,5,6,7-tetramethoxyflavone

Development stage: Preclinical
Modality: Small Molecules

Overview

4'-hydroxy-3,5,6,7-tetramethoxyflavone is a methoxylated flavonoid isolated from the medicinal plant *Varthemia iphionoides*. It has demonstrated potent cytotoxic activity against metastatic prostate cancer cell lines, specifically PC3 and DU145, with IC50 values in the low micromolar range. The compound's mechanism of action involves the induction of cell-cycle arrest (G2/M phase in PC3 cells and S-phase in DU145 cells) and the promotion of apoptosis through the depolarization of the mitochondrial membrane. In silico ADMET profiling suggests favorable drug-likeness, positioning it as a promising lead scaffold for the development of novel prostate cancer therapeutics.

Other names: 3,5,6,7-tetramethoxy-4'-hydroxyflavoneQuercetagetin 3,5,6,7-tetramethyl ether

Beyond the preview

Go deeper on 4'-hydroxy-3,5,6,7-tetramethoxyflavone.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4'-hydroxy-3,5,6,7-tetramethoxyflavone.

Explore the full profile